Enfuvirtidacetat (T-20)
Alias:Fuzeon
Reihenfolge:CH3CO-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu- Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH2
Cas-Nr. : 159519-65-0
Molekularformel : C204H301N51O64
Molekulargewicht : 4492
Reinheit (HPLC) : 98.0%Mindest.
Aussehen : Weißer bis cremefarbener amorpher Feststoff
Einzelne Verunreinigung (HPLC) : 0.5%max
Aminosäurezusammensetzung : ±10 % der Theorie
Peptidgehalt (N%) : ≥80,0 %
Wassergehalt (CarlFischer) : ≤8,0 %
Trifluoracetat-Gehalt(HPIC) : ≤12,0 %
FRAU (ESI) : Konsistent
Massenbilanz : 95.0~105,0 %
Klasse : Pharmazeutische Klasse
Lagerung: Abgeschlossen, unter 2 ~ 8℃ Konservierung
Verwendungszweck : Behandlungsoption für Patienten, die an HIV/AIDS erkrankt sind.
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. It binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected.
Enfuvirtide (GASTHAUS) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).
